Stem cell treatment in Amyotrophic Lateral Sclerosis

Area of Science:

• Neuroscience
• Regenerative Medicine
• Stem Cell Biology

Background:

• Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease affecting motor neurons.
• Reactive astrogliosis and microglia activation play a role in ALS pathogenesis.
• Encapsulating neurons with healthy cells can prevent motor neuron death, suggesting a therapeutic avenue.

Purpose of the Study:

• To evaluate the safety and efficacy of autologous mesenchymal stem cell (MSC) transplantation in patients with Amyotrophic Lateral Sclerosis (ALS).
• To assess the long-term effects of intraspinal MSC injections on disease progression and patient outcomes.

Main Methods:

• MSCs were isolated from the bone marrow of 9 definite ALS patients.
• In vitro characterization of MSCs included growth kinetics, immunophenotype, telomere length, and karyotype analysis.
• Patients received intraspinal injections of autologous MSCs, followed by a 4-year monitoring period.

Main Results:

• In vitro expansion of MSCs showed no significant differences between donors or patients.
• Intraspinal MSC injections were safe, with no acute or late adverse events observed.
• No spinal cord volume changes or abnormal cell proliferation were detected.
• Four patients demonstrated a significant slowing in the decline of forced vital capacity and ALS-FRS scores.

Conclusions:

• Autologous MSCs are a viable option for cell-based therapy in ALS.
• Intraspinal injection of MSCs is safe for ALS patients in the long term.
• Further investigation in a larger Phase 1 study is warranted to confirm these findings.